US Edition
Sinocare withdraws FDA submission, turns to next-gen CGM
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Sinocare withdraws FDA submission, turns to next-gen CGM
The iCan i3 CGM. [Image courtesy of Sinocare]Sinocare announced recently that it withdrew its FDA submission for the first-generation iCan i3 continuous glucose monitor (CGM). The company withdrew the FDA 510(k) submission as it looks to instead expedite bringing its next-gen solution to the market. China-based Sinocare designed the iCan i3 CGM for ease of use, with no scanning, no fingersticks and real-time alerts. It has a 15-day wear life and…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
